Axitinib

(Inlyta®)

Inlyta®

Drug updated on 11/9/2023

Dosage FormTablet (oral; 1 mg, 5 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
  • Indicated in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC.
  • Indicated as a single agent, for the treatment of advanced RCC after failure of one prior systemic therapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Inlyta (axitinib) Prescribing Information.2022Pfizer Inc., New York, NY

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: a Bayesian network meta-regression analysis.2023Frontiers in Oncology
Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan2023Journal of Medical Economics
First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. 2023The Cochrane Database of Systematic Reviews
Efficacy and Safety of Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma: A Systematic Review of Clinical Trials. 2023Hematology/Oncology and Stem Cell Therapy
Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: A systematic review and network meta‐analysis of safety. 2023Cancer Medicine
A systematic review to summarize treatment patterns, guidelines, and characteristics of patients with renal cell carcinoma in the Asia-Pacific region.2023Expert Review of Anticancer Therapy
Clinical outcomes and adverse events after first-line treatment in metastatic renal cell carcinoma: a systematic review and network meta-analysis. 2022The Journal of Urology
Second line treatments for advanced hepatocellular carcinoma: a systematic review and Bayesian network meta analysis. 2022Clinical and Experimental Medicine
Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis. 2022European Association of Urology
Systemic therapy for metastatic renal cell carcinoma in the first‑line setting: a systematic review and network meta‑analysis.2021Cancer Immunology, Immunotherapy
A living, interactive systematic review and network meta-analysis of first-line treatment of metastatic renal cell carcinoma. 2021European Association of Urology
Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: a systematic review and meta-analysis. 2021European Journal of Cancer
A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.2021Journal of Clinical Pharmacy and Therapeutics
Avelumab with axitinib for untreated advanced renal cell carcinoma.2020NICE
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma.2020NICE
Targeted therapy for metastatic renal cell carcinoma. 2020Cochrane Database of Systematic Reviews
What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis.2020BMJ Open
First-line treatments for advanced renal cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis.2020Therapeutic Advances in Medical Oncology
Comparative efficacy of first-line immune-based combination therapies in metastatic renal cell carcinoma: a systematic review and network meta-analysis.2020Cancers
The clinical significance of routine risk categorization in metastatic renal cell carcinoma and its impact on treatment decision-making: a systematic review.2020Future Oncology
First-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis.2019European Urology
Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: a Bayesian network analysis.2019EBioMedicine
Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis.2019BMJ Open
Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.2018NIHR
First-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis. 2018European Urology

Clinical Practice Guidelines

Document TitleYearSource
Kidney cancer, version 3.2022. 2022Journal of the National Comprehensive Cancer Network
EAU guidelines on renal cell carcinoma.2021European Association of Urology
Kidney cancer, version 1.2021.2020Journal of the National Comprehensive Cancer Network
SEOM clinical guideline for treatment of kidney cancer (2019).2020Clinical and Translational Oncology